ConfometRx is developing a platform of structure-based drug development tools to facilitate target validation, lead identification, and lead optimization for G protein coupled receptor (GPCR) targets. This platform includes: the production of pure, functional GPCRs for high-resolution structure determination by crystallography, and the engineering of GPCRs to facilitate crystal formation; the efficient and economical expression of GPCRs for NMR-based drug discovery applications; and the generation of receptor-specific, functional antibodies for target validation, therapeutics and GPCR crystallography.
Founder, Dr. Kobilka is Professor of Medicine, and Molecular and Cellular Physiology at Stanford University. He has been working in the G protein coupled receptor field more than 22 years.